FrancophonIA/ELRC3.0 huggingface dataset:
English: Patiromer was not genotoxic in the reverse mutation test (Ames assay), chromosome aberration or rat micronucleus assays.
Croatian: Patiromer nije bio genotoksičan u testu povratnih mutacija (Amesov test), testu kromosomske aberacije ili mikronukleus testu na štakorima.
English: In healthy adult subjects, patiromer caused a dose dependent increase in faecal potassium excretion, and a corresponding decrease in urinary potassium excretion with no change in serum potassium.
Croatian: U zdravih odraslih ispitanika patiromer je uzrokovao o dozi ovisno povećanje izlučivanja kalija putem fecesa i odgovarajuće smanjenje izlučivanja kalija putem urina, bez promjene kalija u serumu.
English: • ciprofloxacin: a medicine to treat bacterial infections
Croatian: • ciprofloksacin: lijek za liječenje bakterijskih infekcija
English: • You may add more water to the mixture to help you swallow the medicine.
Croatian: • Mješavini po potrebi možete dodati još vode kako biste olakšali gutanje lijeka.
English: The majority of the adverse reactions (ARs) reported from trials were gastrointestinal disorders, with the most frequently reported ARs being constipation (6.2%), diarrhoea (3%), abdominal pain (2.9%), flatulence (1.8%) and hypomagnesaemia (5.3%).
Croatian: Većina nuspojava prijavljena u ispitivanjima bili su poremećaji probavnog sustava, pri čemu su najčešće prijavljivane nuspojave konstipacija (6,2 %), proljev (3 %), bol u abdomenu (2,9 %), flatulencija (1,8 %) i hipomagnezemija (5,3 %).
English: If a dose is missed, the missed dose should be taken as soon as possible on the same day.
Croatian: Ako bolesnik propusti uzeti dozu, propuštenu je dozu potrebno uzeti što je prije moguće istog dana.
English: Veltassa is used to treat adults with high levels of potassium in their blood.
Croatian: Veltassa je namijenjena za liječenje odraslih s visokim razinama kalija u krvi.
English: Since excessive doses of Veltassa may result in hypokalaemia, serum potassium levels should be monitored.
Croatian: Budući da prevelike doze lijeka Veltassa mogu za posljedicu imati hipokalemiju, potrebno je pratiti razine kalija u serumu.
English: In vitro studies have shown no potential interaction of patiromer with the following active substances: allopurinol, amoxicillin, apixaban, acetylsalicylic acid, atorvastatin, cephalexin, digoxin, glipizide, lisinopril, phenytoin, riboflavin, rivaroxaban, spironolactone and valsartan.
Croatian: In vitro ispitivanja nisu pokazala moguću interakciju patiromera sa sljedećim djelatnim tvarima: alopurinol, amoksicilin, apiksaban, acetilsalicilatna kiselina, atorvastatin, cefaleksin, digoksin, glipizid, lizinopril, fenitoin, riboflavin, rivaroksaban, spironolakton i valsartan.
English: Do not use this medicine after the expiry date which is stated on the carton or sachet after “EXP”.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji ili vrećici iza oznake “Rok valjanosti”.
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Croatian: U svakoj skupini učestalosti, nuspojave su prikazane redoslijedom prema manjoj ozbiljnosti.
English: If you stop taking Veltassa
Croatian: Ako prestanete uzimati lijek Veltassa
English: Patiromer works by binding potassium in the gastrointestinal tract and thus the serum concentration is not relevant for its efficacy.
Croatian: Patiromer djeluje vezanjem kalija u probavnom sustavu, pa zato koncentracija u serumu nije značajna za njegovu djelotvornost.
English: Mean baseline serum potassium values were 4.71 mEq/L for patiromer and 4.68 mEq/L for placebo.
Croatian: Srednje vrijednosti kalija u serumu na početku ispitivanja bile su 4,71 mEq/l za patiromer i 4,68 mEq/l za placebo.
English: There is limited experience in patients with serum potassium concentrations greater than 6.5 mmol/L.
Croatian: Postoji ograničeno iskustvo s bolesnicima kod kojih je koncentracija kalija veća od 6,5 mmol/l.
English: Decreases in serum potassium with patiromer treatment were maintained over 1 year of chronic treatment as shown in Figure 1, with a low incidence of hypokalaemia (2.3%) and the majority of subjects reaching (97.7%) and maintaining target serum potassium levels (overall during maintenance period, serum potassium was within the target range for approximately 80% of the time).
Croatian: Smanjenja kalija u serumu kod liječenja patiromerom održana su tijekom 1 godine kroničnog liječenja, kao što je prikazano na Slici 1, uz malu incidenciju hipokalemije (2,3 %) pri čemu je većina ispitanika (97,7 %) postigla i održala ciljne razine kalija u serumu (tijekom cijelog razdoblja održavanja, kalij u serumu bio je unutar ciljnog raspona otprilike 80 % vremena).
English: The effect of treatment with patiromer for up to 52 weeks was evaluated in an open label study of 304 hyperkalaemic patients with CKD and type 2 diabetes mellitus on stable doses of a RAAS inhibitor.
Croatian: Učinak liječenja patiromerom do 52 tjedna bio je ocijenjen u otvorenom ispitivanju na 304 bolesnika s kroničnom bolešću bubrega i hiperkalemijom te dijabetesom mellitus tipa 2 na stabilnim dozama inhibitora RAAS-a.
English: • metformin: a medicine to treat diabetes
Croatian: • metformin: lijek za liječenje dijabetesa
English: Veltassa is a medicine that contains the active substance patiromer.
Croatian: Veltassa je lijek koji sadrži djelatnu tvar patiromer.
English: Other liquids cannot be used as they may contain high amounts of potassium.
Croatian: Ostale tekućine ne smiju se upotrebljavati jer mogu sadržavati visoke razine kalija.
English: • Add about 40 mL (3 tablespoons) of additional water and stir thoroughly.
Croatian: • Dodajte još oko 40 ml (3 velike žlice) vode i dobro promiješajte.
English: Hypomagnesaemia was mild to moderate, with no patient developing a serum magnesium level <1 mg/dL (0.4 mmol/L).
Croatian: Hipomagnezemija je bila blaga do umjerena, ni u jednog bolesnika nije se razvila razina magnezija u serumu < 1 mg/dl (0,4 mmol/l).
English: • Prepare about 40 mL (3 tablespoons) of water in a glass.
Croatian: • U čašu stavite oko 40 ml (3 velike žlice) vode.
English: Other liquids should be avoided as they may contain high amounts of potassium.
Croatian: Ostale tekućine treba izbjegavati jer mogu sadržavati visoke razine kalija.
English: Off white to light brown powder, with occasional white particles.
Croatian: Bjelkasti do svijetlosmeđi prašak, s nešto bijelih čestica.
English: Patiromer is excreted approximately 24 to 48 hours after intake, based on average gastrointestinal transit time.
Croatian: Patiromer se izlučuje približno 24 sata do 48 sati nakon uzimanja, na temelju prosječnog tranzitnog vremena kroz probavni sustav.
English: Patiromer is excreted after approximately 24 to 48 hours, based on average gastrointestinal transit time.
Croatian: Patiromer se izlučuje nakon približno 24 do 48 sati na temelju prosječnog tranzitnog vremena kroz probavni sustav.
English: There are no data from the use of patiromer in pregnant women.
Croatian: Nema podataka o primjeni patiromera u trudnica.
English: Of the 105 patients who were randomised and received study treatment (patiromer 56; placebo 49), mean age was 68.3 years, 60.6% were men, 97.1% were Caucasian, and mean eGFR was 81.3 mL/min.
Croatian: Od 105 bolesnika koji su randomizirani i primili ispitivano liječenje (patiromer 56; placebo 49), srednja dob bila je 68,3 godine, 60,6 % bili su muškarci, 97,1 % bili su bijelci, a srednji eGFR bio je 81,3 ml/min.
English: • severe stomach or bowel problems
Croatian: • imate ozbiljne probleme sa želucem ili crijevima
English: PHARMACEUTICAL FORM AND CONTENTS powder for oral suspension
Croatian: OBLIK I SADRŽAJ prašak za oralnu suspenziju
English: Can be stored below 25°C for up to 6 months.
Croatian: Može se čuvati na temperaturi ispod 25 °C najviše 6 mjeseci.
English: Patiromer is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol complex as a counterion.
Croatian: Patiromer je polimer koji se ne apsorbira i omogućuje izmjenu kationa, a sadrži kompleks kalcija i sorbitola kao protuion.
English: Overall, in the phase 2 and 3 clinical studies, 99.4% of patients were receiving RAAS inhibitor therapy at baseline, 81.2% had CKD with eGFR <60 mL/min/1.73 m2, 72.8% had diabetes mellitus and 48.7% had heart failure.
Croatian: U kliničkim ispitivanjima faze 2 i 3, ukupno 99,4 % bolesnika primalo je terapiju inhibitorima RAAS-a na početku ispitivanja, 81,2 % imalo je kroničnu bolest bubrega (KBB) s eGFR-om < 60 ml/min/1,73 m², 72,8 % je imalo diabetes mellitus, a 48,7 % je imalo zatajenje srca.
English: Daily urinary calcium excretion increased from baseline by 53 mg/day.
Croatian: Dnevno izlučivanje kalcija putem urina povećalo se u odnosu na početak ispitivanja za 53 mg/dan.
English: This prevents potassium from entering your bloodstream and lowers potassium levels in your blood back to normal.
Croatian: Time se sprječava da kalij uđe u krvotok te se razine kalija u krvi snižavaju na normalne.
English: Concomitant administration of patiromer showed reduced bioavailability of ciprofloxacin, levothyroxine and metformin.
Croatian: Pokazalo se da istodobna primjena patiromera smanjuje bioraspoloživost ciprofloksacina, levotiroksina i metformina.
English: Metabolism and nutrition disorders
Croatian: Poremećaji metabolizma i prehrane hipomagnezemija
English: There were also fewer patients in the patiromer group with serum potassium values >5.5 mEq/L (7.3% vs. 24.5%; p=0.027) and more patients on spironolactone 50 mg/day (90.9% versus 73.5%, p=0.022).
Croatian: U skupini koja je primala patiromer također je bilo manje bolesnika s razinama kalija u serumu >5,5 mEq/l (7,3 % naspram 24,5 %; p=0,027) i više bolesnika koji su primali spironolakton u dozi od 50 mg dnevno (90,9 % naspram 73,5 %, p=0,022).
English: If you forget to take Veltassa
Croatian: Ako ste zaboravili uzeti lijek Veltassa
English: Another approximately 40 mL of water should be added, and the suspension stirred again thoroughly.
Croatian: Potrebno je dodati još otprilike 40 ml vode, a zatim ponovno dobro promiješati.
English: More placebo patients (91% [95% CI: 83%, 99%]) developed a serum potassium ≥5.1 mEq/L at any time during Part B than patiromer patients (43% [95% CI: 30%, 56%]), p<0.001.
Croatian: Više bolesnika na placebu (91 % [95 % CI: 83 %, 99 %]) razvilo je razinu kalija u serumu ≥5,1 mEq/l u bilo kojem trenutku tijekom dijela B nego bolesnika koji su primali patiromer (43 % [95 % CI: 30 %, 56 %]), p<0,001.
English: The mean age of patients was 64 years (54% aged 65 and over, 17% aged 75 and over), 58% of patients were men, and 98% were Caucasian.
Croatian: Srednja je dob bolesnika bila 64 godine (54 % u dobi od 65 godina i više, 17 % u dobi od 75 godina i više), 58 % bolesnika bili su muškarci, a 98 % bolesnika bili su bijelci.
English: Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels.
Croatian: Magnezij u serumu potrebno je pratiti najmanje 1 mjesec nakon početka liječenja te je u bolesnika u kojih dođe do smanjenja razina magnezija u serumu potrebno razmotriti nadomještanje magnezija.
English: Veltassa contains calcium as part of the counterion complex.
Croatian: Veltassa sadrži kalcij kao dio protuionskog kompleksa.
English: Concomitant administration of patiromer did however not affect the bioavailability as measured by the area under the curve (AUC) of amlodipine, cinacalcet, clopidogrel, furosemide, lithium, metoprolol, trimethoprim, verapamil and warfarin.
Croatian: Istodobna primjena patiromera nije utjecala na bioraspoloživost, mjerenu površinom ispod krivulje (AUC), amlodipina, sinakalceta, klopidogrela, furosemida, litija, metoprolola, trimetoprima, verapamila i varfarina.
English: • maximum dose: 25.2 g patiromer (the content of one 25.2 g sachet) once daily
Croatian: • maksimalna doza: 25,2 g patiromera (sadržaj jedne vrećice od 25,2 g) jednom dnevno
English: 25.2 g of patiromer, administered once daily for 6 days, resulted in a mean increase in faecal potassium excretion of 1283 mg/day, and a mean decrease in urinary potassium excretion of 1438 mg/day.
Croatian: Uzimanje 25,2 g patiromera jednom dnevno tijekom 6 dana rezultiralo je srednjim povećanjem izlučivanja kalija putem fecesa od 1283 mg/dan te srednjim smanjenjem izlučivanja kalija putem urina od 1438 mg/dan.
English: The mean age of patients was 66 years (59.9% aged 65 and over, 19.7% aged 75 and over), 63% of patients were men, and all were Caucasian.
Croatian: Srednja je dob bolesnika bila 66 godina (59,9 % u dobi od 65 godina i više, 19,7 % u dobi od 75 godina i više), 63 % bolesnika bili su muškarci i svi su bili bijelci.
English: • starting dose: 8.4 g patiromer (the content of one 8.4 g sachet) once daily
Croatian: • početna doza: 8,4 g patiromera (sadržaj jedne vrećice od 8,4 g) jednom dnevno
English: Once you have received Veltassa, it can be stored below 25°C for up to 6 months.
Croatian: Nakon što ste preuzeli lijek Veltassa, možete ga čuvati na temperaturi ispod 25 °C najviše 6 mjeseci.
English: Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.
Croatian: Vezanje kalija smanjuje koncentraciju slobodnog kalija u lumenu probavnog sustava, što rezultira smanjenjem razina kalija u serumu.
English: Patiromer increases faecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract.
Croatian: Patiromer povećava izlučivanje kalija putem fecesa vezanjem kalija u lumenu probavnog sustava.
English: Apple juice or cranberry juice can be used instead of water to prepare the mixture.
Croatian: Za pripremu mješavine, umjesto vode može se upotrijebiti sok od jabuke ili brusnice.
English: For either storage condition, Veltassa should not be used after the expiry date printed on the sachet.
Croatian: U oba slučaja uvjeta čuvanja, lijek Veltassa ne smije se primjenjivati nakon isteka roka valjanosti otisnutog na vrećici.
English: The dose was titrated, as needed, based on the serum potassium level, assessed starting on Day 3 and then at weekly visits to the end of the 4 week treatment period, with the aim of maintaining serum potassium in the target range (3.8 mEq/L to <5.1 mEq/L).
Croatian: Doza je titrana po potrebi na temelju razine kalija u serumu mjerene počevši od 3. dana, a zatim jednom tjedno do kraja 4-tjednog razdoblja liječenja, s ciljem održavanja razine kalija u ciljnom rasponu (3,8 mEq/l do <5,1 mEq/l).
English: The active substance is patiromer (as patiromer sorbitex calcium).
Croatian: Djelatna tvar je patiromer (u obliku patiromer-sorbiteks-kalcija).
English: Serum potassium at the end of treatment, the change from baseline in serum potassium, and the mean dose of patiromer were similar between groups.
Croatian: Kalij u serumu na kraju liječenja, promjena od početne vrijednosti kalija u serumu i srednja vrijednost doze patiromera u obje grupe bili su slični.
English: For the Part A secondary outcome, 76% (95% CI: 70%, 81%) of patients had a serum potassium in the target range of 3.8 mEq/L to <5.1 mEq/L at Part A Week 4.
Croatian: Kao sekundarni ishod u dijelu A, u 76 % (95 % CI: 70 %, 81 %) bolesnika razina kalija u serumu bila je u ciljnom rasponu od 3,8 mEq/l do <5,1 mEq/l u 4. tjednu dijela A.
English: Patients initiated spironolactone at 25 mg/day at the same time as their randomised treatment (patiromer 12.6 g BID or placebo), and were up-titrated to 50 mg/day after Day 14 if serum potassium was >3.5 and ≤5.1 mEq/L.
Croatian: Bolesnici su počeli primati spironolakton u dozi od 25 mg dnevno u isto vrijeme kao i randomizirano liječenje (patiromer 12,6 g dva puta dnevno ili placebo) te im je povećana doza do 50 mg dnevno nakon 14. dana ako je kalij u serumu bio >3,5 i ≤5,1 mEq/l.
English: • levothyroxine: a medicine to treat thyroid hormone deficiency
Croatian: • levotiroksin: lijek za liječenje manjka hormona štitnjače
English: Veltassa contains sorbitol as part of the counterion complex.
Croatian: Veltassa sadrži sorbitol kao dio protuionskog kompleksa.
English: Discontinuing patiromer
Croatian: Prekid liječenja patiromerom
English: The Part B primary endpoint was the change in serum potassium from Part B baseline to the earliest visit at which the patient's serum potassium was first outside of the range of 3.8 to <5.5 mEq/L or to Part B Week 4 if the patient's serum potassium remained in the range.
Croatian: Mjera primarnog ishoda dijela B bila je promjena kalija u serumu u odnosu na početnu vrijednost u dijelu B do prve posjete pri kojoj je razina bolesnikova kalija u serumu prvi put bila izvan raspona od 3,8 do <5,5 mEq/l ili do 4. tjedna dijela B ako je bolesnikova razina kalija u serumu ostala u rasponu.
English: Baseline Serum K+ > 5.5 to < 6.0 mEq/L
Croatian: Početni K+ u serumu > 5,5 do < 6,0 mEq/l
English: • Veltassa 25.2 g powder for oral suspension: each sachet contains 25.2 g of patiromer.
Croatian: • Veltassa 25,2 g prašak za oralnu suspenziju: svaka vrećica sadrži 25,2 g patiromera.
English: In Part B, 107 patients with a Part A baseline serum potassium of 5.5 mEq/L to <6.5 mEq/L and whose serum potassium was in the target range (3.8 mEq/L to <5.1 mEq/L) at Part A Week 4 and still receiving RAAS inhibitor treatment were randomised to continue patiromer or to receive placebo for 8 weeks to evaluate the effect of withdrawing patiromer on serum potassium.
Croatian: U dijelu B, 107 bolesnika s početnom vrijednošću kalija u serumu u dijelu A od 5,5 mEq/l do <6,5 mEq/l u kojih je kalij u serumu bio u ciljnom rasponu (3,8 mEq/l do <5,1 mEq/l) u 4. tjednu u dijelu A, a koji su i dalje primali inhibitor RAAS-a randomizirano je za nastavak primanja patiromera ili primanje placeba tijekom 8 tjedana kako bi se procijenio učinak ukidanja terapije patiromerom na kalij u serumu.
English: Patiromer has the potential to bind some oral co administered medicinal products, which could decrease their gastrointestinal absorption.
Croatian: Patiromer može vezati neke lijekove koji se istodobno peroralno primjenjuju, što može smanjiti njihovu apsorpciju u probavnom sustavu.
English: Mean (95% Cl) Serum Potassium (mEq/L)
Croatian: Srednja vrijednost (95 % CI) kalija u serumu (mEq/l)
English: The benefits and risks of administering patiromer should be carefully evaluated in patients with current or history of severe gastrointestinal disorders, before and during treatment.
Croatian: Prije i tijekom liječenja potrebno je pažljivo procijeniti koristi i rizike primjene patiromera u bolesnika s trenutačnim ili anamnezom teških poremećaja probavnog sustava.
English: No special dose and administration guidelines were applied to these patients in clinical studies.
Croatian: U kliničkim ispitivanjima za te se bolesnike nisu primjenjivale nikakve posebne smjernice za doziranje i primjenu.
English: How to take Veltassa
Croatian: Kako uzimati lijek Veltassa
English: Constipation Diarrhoea Abdominal pain Flatulence
Croatian: Poremećaji probavnog sustava konstipacija proljev bol u abdomenu flatulencija mučnina povraćanje
English: The mixture should be taken within 1 hour of initial suspension.
Croatian: Mješavinu je potrebno popiti u roku od jednog sata nakon pripreme suspenzije.
English: Uncommon, may affect up to 1 in 100 people: nausea vomiting
Croatian: Manje često, mogu se javiti u do 1 na 100 osoba:
English: INFORMATION IN BRAILLE VELTASSA 25.2 G
Croatian: 16. PODACI NA BRAILLEOVOM PISMU VELTASSA 25,2 G
English: • Veltassa 16.8 g powder for oral suspension: each sachet contains 16.8 g of patiromer.
Croatian: • Veltassa 16,8 g prašak za oralnu suspenziju: svaka vrećica sadrži 16,8 g patiromera.
English: Patients on dialysis
Croatian: Bolesnici na dijalizi
English: Patients may store Veltassa below 25°C for up to 6 months.
Croatian: Bolesnici mogu čuvati lijek Veltassa ispod 25 °C najviše 6 mjeseci.
English: How to store Veltassa
Croatian: Kako čuvati lijek Veltassa
English: In clinical studies, serum magnesium values <1.4 mg/dL (0.58 mmol/L) occurred in 9% of patients treated with patiromer.
Croatian: U kliničkim ispitivanjima u 9 % bolesnika liječenih patiromerom vrijednosti magnezija u serumu bile su < 1,4 mg/dl (0,58 mmol/l).
English: Adverse reactions are listed below by system organ class and by frequency.
Croatian: Nuspojave su navedene u nastavku prema klasifikaciji organskih sustava i učestalosti.
English: Mean serum potassium levels and change in serum potassium from Part A Baseline to Part A Week 4 is shown in Table 1.
Croatian: Srednje razine kalija u serumu i promjena razina kalija u serumu od početne vrijednosti u dijelu A do 4. tjedna u dijelu A prikazane su u Tablici
English: The potential of patiromer to enable concomitant RAAS inhibitor treatment was also assessed in part B. Fifty two percent (52%) of subjects receiving placebo discontinued RAAS inhibitor treatment because of recurrent hyperkalaemia compared with 5% of subjects treated with patiromer.
Croatian: Pedeset dva posto (52 %) ispitanika koji su primali placebo prestali su uzimati inhibitor RAAS-a zbog opetovane hiperkalemije u usporedbi s 5 % ispitanika koji su primali patiromer.
English: INFORMATION IN BRAILLE VELTASSA 16.8 G
Croatian: 16. PODACI NA BRAILLEOVOM PISMU VELTASSA 16,8 G
English: In patients with a baseline serum potassium of >5.0 to 5.5 mEq/L who received an initial dose of 8.4 g patiromer per day, the mean daily dose was 14 g; in those with a baseline serum potassium of >5.5 to <6.0 mEq/L who received an initial dose of 16.8 g patiromer per day, the mean daily dose was 20 g during the entire study.
Croatian: Za bolesnike s početnom vrijednošću kalija u serumu od >5,0 do 5,5 mEq/l koji su primali početnu dozu od 8,4 g patiromera dnevno, srednja dnevna doza bila je 14 g, a za one s početnom vrijednošću kalija u serumu od >5,5 do <6,0 mEq/l koji su primali početnu dozu od 16,8 g patiromera dnevno, srednja dnevna doza bila je 20 g tijekom cijelog ispitivanja.
English: The mean daily doses of patiromer were 13 g and 21 g in patients with serum potassium of 5.1 to <5.5 mEq/L and 5.5 to <6.5 mEq/L, respectively.
Croatian: Srednje dnevne doze patiromera bile su 13 g u bolesnika s razinom kalija u serumu od 5,1 do <5,5 mEq/l, odnosno 21 g u bolesnika s razinom kalija u serumu 5,5 do <6,5 mEq/l.
English: Veltassa works by attaching to potassium in your gut.
Croatian: Veltassa djeluje vezanjem kalija u crijevima.
English: Veltassa 8.4 g powder for oral suspension Veltassa 16.8 g powder for oral suspension Veltassa 25.2 g powder for oral suspension patiromer (as patiromer sorbitex calcium)
Croatian: Veltassa 8,4 g prašak za oralnu suspenziju Veltassa 16,8 g prašak za oralnu suspenziju Veltassa 25,2 g prašak za oralnu suspenziju patiromer (u obliku patiromer-sorbiteks-kalcija)
English: 4.7 Effects on ability to drive and use machines Patiromer has no or negligible influence on the ability to drive and use machines.
Croatian: Patiromer ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Patients with a baseline serum potassium of 5.1 mEq/L to <5.5 mEq/L (mmol/L) received a starting dose of 8.4 g patiromer per day (as a divided dose) and patients with a baseline serum potassium of 5.5 mEq/L to <6.5 mEq/L received a starting dose of 16.8 g patiromer per day (as a divided dose).
Croatian: Bolesnici s početnom vrijednošću kalija u serumu od 5,1 mEq/l do <5,5 mEq/l (mmol/l) dobivali su početnu dozu od 8,4 g patiromera dnevno (u obliku podijeljene doze), a bolesnici s početnom vrijednošću kalija u serumu od 5,5 mEq/l do <6,5 mEq/l dobivali su početnu dozu od 16,8 g patiromera dnevno (u obliku podijeljene doze).
English: The ability of patiromer to enable concomitant spironolactone treatment was investigated in a randomised, double-blind, placebo-controlled study in heart failure patients who were clinically indicated to receive AA.
Croatian: U randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju u bolesnika sa zatajenjem srca kod kojih je klinički indicirano primanje antagonista aldosterona istraživana je sposobnost patiromera da omogući istodobno liječenje spironolaktonom.